Valuation: Cytokinetics, Incorporated

Market Cap 8.52B 7.64B 7.07B 6.4B 11.96B 811B 12.1B 84.49B 33.65B 425B 31.97B 31.29B 1,348B P/E 2026 *
-10.1x
P/E 2027 * -13.3x
Enterprise Value 7.36B 6.6B 6.1B 5.53B 10.33B 701B 10.45B 72.97B 29.06B 367B 27.61B 27.03B 1,164B EV / Sales 2026 *
47.1x
EV / Sales 2027 * 17.4x
Free-Float
98.21%
Yield 2026 *
-
Yield 2027 * -
1 day-0.39%
1 week-2.51%
Current month-7.02%
1 month-7.38%
3 months-22.87%
6 months+0.97%
Current year-3.56%
1 week 60.14
Extreme 60.145
62.44
1 month 59.78
Extreme 59.785
67.27
Current year 58.43
Extreme 58.43
88.31
1 year 58.05
Extreme 58.05
88.31
3 years 29.31
Extreme 29.31
110.25
5 years 25.98
Extreme 25.98
110.25
10 years 5.75
Extreme 5.75
110.25
Manager TitleAgeSince
Chief Executive Officer 62 2006-12-31
Director of Finance/CFO 55 2024-05-07
Chief Operating Officer - 2018-02-28
Director TitleAgeSince
Director/Board Member 62 2006-12-31
Chairman 81 2022-04-07
Director/Board Member 78 2011-02-08
Date Insider Type Main position Quantity % Market Cap. Importance
10/12/26 Exercice

Chief Executive Officer

22,500 0.0162%
10/6/26 Exercice

Chief Technology Officer

10,500 0.0076%
9/28/26 Exercice

Chief Executive Officer

22,500 0.0162%
Change 5-day change 1-year change 3-year change Capi.($)
-0.39%-2.51%-1.11%+93.07% 8.55B
+0.65%-3.36%+36.98%+60.50% 63.48B
+1.76%+1.27%+11.82%+81.21% 54.55B
-0.94%+0.99%+10.45%+100.19% 53.59B
+2.76%+0.87%+27.92%+55.07% 44.75B
+2.00%-3.39%+17.83%+119.04% 41.62B
+1.34%-2.86%+224.43%+914.08% 39.91B
+0.64%-3.95%+11.15%+45.57% 32.47B
+29.06%+47.63%+107.12%+92.73% 26.7B
-0.91%+1.41%+25.48%-9.11% 23.36B
Average +3.60%-0.30%+47.21%+155.24% 38.9B
Weighted average by Cap. +2.88%+0.00%+47.07%+159.60%

Financials

2026 *2027 *
Net sales 156M 140M 130M 117M 219M 14.89B 222M 1.55B 618M 7.79B 587M 574M 24.74B 429M 385M 356M 322M 602M 40.82B 609M 4.25B 1.69B 21.36B 1.61B 1.57B 67.81B
Net income -805M -722M -667M -604M -1.13B -76.63B -1.14B -7.98B -3.18B -40.1B -3.02B -2.96B -127B -652M -585M -541M -490M -915M -62.07B -926M -6.46B -2.57B -32.48B -2.45B -2.39B -103B
Net Debt -1.16B -1.04B -964M -873M -1.63B -111B -1.65B -11.52B -4.59B -57.91B -4.36B -4.27B -184B -1.06B -954M -882M -799M -1.49B -101B -1.51B -10.55B -4.2B -53B -3.99B -3.91B -168B
Projected Income Statement - Annual - Cytokinetics, Incorporated
Logo Cytokinetics, Incorporated
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
Employees
673
Date Price Change Volume
26-10-28 US$61.28 -0.39% 1,274,167
26-10-27 US$61.52 +1.30% 1,148,268
26-10-26 US$60.73 -0.82% 783,238
26-10-23 US$61.23 -1.76% 985,632
26-10-22 US$62.33 -0.84% 2,061,246
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - Cytokinetics, Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
61.28USD
Average target price
109.20USD
Spread / Average Target
+78.20%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cytokinetics, Incorporated
  1. Stock Market
  2. Stocks
  3. CYTK Stock